Molecular alterations characterizations such as isocitrate dehydrogenase IDH1/2 mutations, 1p/19q codeletion, and MGMT promoter methylation, have improved the accuracy of diagnostics, prognostics, and prediction of treatment response for glioma patients. This evidence concerns the gene IDH1 and central nervous system cancer.